Several large clinical trials have evaluated
whether antiretroviral drugs can prevent HIV infection in healthy populations.
The HPTN 052 trial was designed to evaluate
whether antiretroviral therapy reduces sexual transmission of HIV.
Not exact matches
The
antiretroviral drugs, of course, can only work if they are in the blood or tissues when HIV attempts to establish an infection, so nonadherent participants who are in treatment arms of these studies make it exceedingly difficult to tease out
whether infections occurred because of the drug failure or their own behavior.
«The HPTN 052 trial was designed to address two questions:
whether providing
antiretroviral therapy to an HIV - infected person would prevent HIV transmission to a sexual partner, and
whether earlier
antiretroviral therapy offered long - lasting health benefits, and the answer to both is a resounding yes.»
Dr. Gendelman said the next step is to formulate URMC - 099 with drug cocktails and investigate
whether such a chemical marriage can extend the half lives of many other
antiretrovirals and a spectrum of other drugs.
«This suggests lowering viral replicative capacity and the resulting immune activation might have benefits, in terms of morbidity and mortality, for individuals
whether they remain treatment naïve or go on
antiretroviral therapy.
«To propel the field forward, we need to identify biomarkers that could, for instance, accurately predict
whether treatments are working without the risk of taking patients off their
antiretroviral drugs.»
Inflammation can be a driving factor for heart disease, but in the study, low vitamin D was not linked to higher levels of inflammation markers. Additional research could determine
whether those who are starting
antiretroviral therapy would see better immune recovery if they took a vitamin D supplement.
History also teaches us the greatest advances in medicine have come from scientific breakthroughs,
whether the discovery of antibiotics, or improved public health practices, vaccines for smallpox and polio and many other infectious diseases,
antiretroviral drugs that can return AIDS patients to productive lives, pills that can control certain types of blood cancers, so many others.
Studies have also shown that clinicians — as well as pharmacists — and users are concerned about the impact of increased access to EC on sexual risk - taking behaviors and sexually transmitted infections (STIs).8 - 10 Recent research in the field of STI and human immunodeficiency virus (HIV) prevention has shown that sexual risk - taking behaviors and unprotected intercourse in men have increased after the introduction of highly active
antiretroviral therapy.11, 12 No study has yet tested
whether increased access to EC might increase STI risk by affecting sexual behavior, including frequency of intercourse and number of partners.
Stigma can also make it difficult to seek care,
whether it is making that initial doctor's visit for an HIV test, asking a doctor to prescribe preventive medication, or picking up lifesaving
antiretrovirals from a small - town pharmacy.